Efprezimod alfa + Placebo + Methotrexate + Tacrolimus
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hematopoietic Stem Cell Transplantation
Conditions
Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
Trial Timeline
Jan 5, 2021 → Nov 5, 2021
NCT ID
NCT04095858About Efprezimod alfa + Placebo + Methotrexate + Tacrolimus
Efprezimod alfa + Placebo + Methotrexate + Tacrolimus is a phase 3 stage product being developed by Merck for Hematopoietic Stem Cell Transplantation. The current trial status is terminated. This product is registered under clinical trial identifier NCT04095858. Target conditions include Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04095858 | Phase 3 | Terminated |
Competing Products
20 competing products in Hematopoietic Stem Cell Transplantation